CLAIMS:

1. A treated core comprising:

a core substrate; and

apixaban and a carrier on the core substrate,

wherein the treated core comprises from 0.001% w/w to 0.20% w/w apixaban, wherein the apixaban and the carrier are in a layer formed on a surface of the core substrate, wherein the apixaban and the carrier are applied to the surface of the core substrate by a spray-layered dispersion process carried out with a concentration of apixaban in a solvent below the solubility limit.

2. The treated core of claim 1, wherein the core substrate is a sugar bead or sphere, or a microcrystalline cellulose, lactose, or mannitol particle.

3. The treated core of claim 1 or 2, having a core size from about 150 microns to about 355 microns.

4. A formulation comprising at least one said treated core of any one of claims 1-3.

5. The formulation of claim 4, which:

(a) has an apixaban content from about 0.09% w/w to about 0.11% w/w;

(b) has a carrier content from about 9% w/w to about 11% w/w;

(c) has a core substrate content from about 89% w/w to about 91% w/w; or

(d) has an apixaban content of about 0.1% w/w.

6. The formulation of claim 4 or 5, wherein the at least one said treated core is in a capsule.

7. The formulation of any one of claims 4-6, wherein the capsule is a gelatin capsule or an HPMC capsule or a sprinkle capsule.

8. The formulation of claim 6 or 7, wherein the capsule comprises about 0.1 mg apixaban.

9. A treated core of any one of claims 1-3 for use in treating a thromboembolic disorder in a subject in need thereof comprising:
dispersing and/or dissolving at least one said treated core in a liquid carrier and
administering the liquid carrier to the subject.

10. The treated core for use according to claim 9, wherein the liquid carrier is a food or beverage.

11. The treated core for use according to claim 9 or 10, wherein the subject is a neonate.

12. The treated core of any one of claims 1-3 or the formulation of any one of claims 4-8 for use in a treatment of a thromboembolic disorder.

13. The formulation of claim 4 or 5, wherein the formulation comprises about 0.1 mg to about 0.4 mg of apixaban.

14. The formulation of claim 13, wherein the formulation comprises about 0.2 mg of apixaban.

15. The formulation of claim 13, wherein the formulation comprises about 0.3 mg of apixaban.

16. The formulation of claim 13, wherein the formulation comprises about 0.4 mg of apixaban.

17. The formulation of any one of claims 13-16, wherein the at least one treated core is in a capsule.

18. The formulation of claim 17, wherein the capsule is a sprinkle capsule.